ArticleMedicina oral, patologia oral y cirugia bucal2025
Emerging trends in pharmacological treatment of inferior alveolar nerve sensory disorders: a scoping review.
Article in Medicina oral, patologia oral y cirugia bucal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSensory disorders of the inferior alveolar nerve, often arising from dental procedures, markedly impact the quality of life of patients. This article proposes a scoping review to analyze emerging trends in pharmacological treatment for these disorders, addressing scientific gaps and clinical practices. MATERIAL AND
methodsThe review followed the PRISMA-ScR protocol, conducting data searches across various databases, including PubMed and Cochrane, until March 2024. Case studies and series related to patients with sensory disorders of the inferior alveolar nerve undergoing pharmacological treatment were included.Parte inferior do formulário Results: Out of the initial 542 records, 7 studies were included after rigorous selection, displaying low bias risk. Medicinal therapies varied, encompassing analgesics, corticosteroids, anesthetics, and vitamin complexes. Dipyrone stood out in the preoperative phase, while prednisone proved effective in paresthesias. Selegiline, an MAO-B inhibitor, introduced an innovative approach.
conclusionsAgents such as selegiline offer an innovative approach to sensory restoration, while corticosteroids exhibit variable efficacy. Dipyrone is effective in preoperative pain control, and vitamin complexes provide regenerative and neuroprotective benefits. However, it is essential to consider that treatment success may vary and to address the individual needs of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.